LY 3526318
Alternative Names: LY-3526318; LY356318; TRPA1 Antagonist I - Eli LillyLatest Information Update: 24 Jan 2023
At a glance
- Originator Eli Lilly and Company
- Class Analgesics; Non-opioid analgesics; Small molecules
- Mechanism of Action TRPA1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Neuropathic pain; Pain
Most Recent Events
- 09 Jan 2023 Eli Lilly and Company withdraws a phase I trial prior to enrolment in Healthy volunteers in Japan (PO) due to a business decision (NCT05580250)
- 14 Oct 2022 Eli Lilly and Company plans a phase I safety and pharmacokinetics trial in healthy volunteers in Japan (PO) (NCT05580250)
- 13 Oct 2022 Eli Lilly and Company completes a phase II trial in Neuropathic pain in USA and Puerto Rico (PO) (NCT05177094)